Shares of Egalet Corp. (NASDAQ:EGLT) traded down 2.8% during trading on Wednesday . The company traded as low as $8.63 and last traded at $8.69, with a volume of 134,164 shares traded. The stock had previously closed at $8.94.

A number of analysts recently commented on the company. Zacks Investment Research lowered Egalet Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. Cantor Fitzgerald set a $21.00 price objective on Egalet Corp. and gave the stock a “buy” rating in a research report on Saturday, August 6th.

The company’s market cap is $201.99 million. The stock has a 50-day moving average price of $7.16 and a 200 day moving average price of $6.56.

Egalet Corp. (NASDAQ:EGLT) last issued its earnings results on Thursday, August 4th. The specialty pharmaceutical company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by $0.15. The business earned $3.45 million during the quarter, compared to analyst estimates of $3.83 million. During the same period in the previous year, the firm posted ($1.03) earnings per share. The firm’s quarterly revenue was up 259.4% on a year-over-year basis. On average, equities analysts expect that Egalet Corp. will post ($3.47) EPS for the current year.

In other news, CEO Robert S. Radie sold 5,000 shares of the stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $5.07, for a total value of $25,350.00. Following the completion of the sale, the chief executive officer now owns 259,900 shares of the company’s stock, valued at $1,317,693. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Robert S. Radie sold 15,000 shares of the stock in a transaction dated Wednesday, July 6th. The shares were sold at an average price of $5.01, for a total value of $75,150.00. Following the completion of the sale, the chief executive officer now directly owns 259,900 shares of the company’s stock, valued at approximately $1,302,099. The disclosure for this sale can be found here.

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.